NEW HAVEN, Conn., March 31 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. today announced that Kevin Rakin, President and Chief Executive Officer of Genaissance, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York at 11:30 a.m. Eastern time on Monday, April 4, 2005.
Mr. Rakin's remarks will also be available live via an audio webcast that can be accessed through the Company's website at: http://www.genaissance.com/ .
Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy is designed to enable Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit the Company's website at: http://www.genaissance.com/ .
Genaissance Pharmaceuticals, Inc.
CONTACT: Kevin Rakin, President & Chief Executive Officer of GenaissancePharmaceuticals, Inc., +1-203-773-1450; or Rhonda Chiger (investors)Rx Communications Group, +1-917-322-2569; Tom Redington (media) of Redington,Inc., +1-203-222-7399, both for Genaissance Pharmaceuticals, Inc.